• GSK 2837808A: From LDHA Flux to Immune Signaling

  2026-09-03

  GSK 2837808A is a selective lactate dehydrogenase A inhibitor for separating glycolytic flux from downstream tumor signaling. This article develops an assay strategy that connects lactate reduction and glucose consumption reduction to the NAT1–ENO1–lactate–PD-L1 pathway without overstating preclinical evidence.

• Foretinib: From Kinase Potency to Translational Signal

  2026-09-02

  Foretinib (GSK1363089) is more than a potent multikinase reagent: it is a strategic tool for linking Met and VEGFR pathway biology with interpretable measurements of proliferation, motility, invasion, and metastasis. This thought-leadership guide shows translational researchers how to pair its mechanistic breadth with endpoint-aware assay design, orthogonal validation, and disciplined interpretation of preclinical models.

• SHC-1 Control of CFTR Surface Abundance

  2026-09-02

  The reference study shows that MAPK/SHC-1-dependent internalization of CFTR is conserved across airway and intestinal epithelial models, while the response to SHC-1 inhibition is strongly cell-type dependent. Its principal contribution is to separate pathway conservation from intervention specificity, highlighting why plasma-membrane abundance must be assessed alongside unrelated surface proteins.

• IAM-LC and LEKC for Pulmonary Permeability

  2026-09-01

  The reference study provides a direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for biomimetic drug–membrane partitioning. Its results show that LEKC more closely represented apparent pulmonary permeability, whereas IAM-LC offered broader compound coverage, simpler operation, and stronger potential for automated screening.

• NAT1–ENO1–Lactate Signaling in Colorectal Cancer

  2026-09-01

  A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator that restrains ENO1 activity, lactate production, and TRAF6-dependent PD-L1 stabilization in colorectal cancer. The findings provide a preclinical framework for testing lactate-pathway perturbation alongside immune checkpoint blockade, while emphasizing that the proposed mechanism still requires pharmacological and clinical validation.

• FGFR–TGFβ–PI3K/AKT Control of Periostin

  2026-08-31

  Labrèche et al. identify a signaling cross talk that controls periostin expression in Neu-positive breast cancer models, linking FGFR, TGFβ, PKC, and PI3K/AKT activity. The study distinguishes stromal constitutive expression from epithelial tumor-cell acquisition of periostin and provides a framework for interpreting context-dependent extracellular-matrix regulation.

• NMDA for Glaucoma Excitotoxicity Research

  2026-08-31

  NMDA provides a direct, controllable way to model receptor-driven calcium overload, oxidative stress, and retinal ganglion cell injury. This workflow connects excitotoxicity research with ferroptosis-focused readouts and BMP4-GPX4 rescue experiments in glaucoma models.

• Heparin Sodium as a Mechanistic HSPG Control

  2026-08-30

  Heparin sodium is a glycosaminoglycan anticoagulant best known for antithrombin activation, but its polyanionic structure also makes it a valuable control for heparan sulfate proteoglycan-dependent uptake studies. This article develops a practical framework for interpreting coagulation assays and nanovesicle experiments without conflating established evidence with emerging hypotheses.

• Grazoprevir/Elbasvir Therapy for HCV: Evidence

  2026-08-29

  The reference article explains why combining the NS3/4A protease inhibitor grazoprevir with the NS5A inhibitor elbasvir provided a potent, interferon-free strategy for chronic HCV infection. Its synthesis of clinical efficacy, resistance, safety, and special-population data shows how complementary target coverage can support high SVR rates while reducing treatment complexity.

• Oteseconazole (VT-1161) for Candida Assays

  2026-08-28

  Oteseconazole (VT-1161) supports concentration-controlled Candida susceptibility testing, resistant-isolate studies, and mechanism-informed antifungal workflows. Its strong fungal CYP51 selectivity and activity across multiple Candida species make it useful for separating target-specific potency from solvent, growth, and transporter-related confounders.

• Instant Clot-Forming TXA–SNAP–Propolis Dressings

  2026-08-28

  Nguyen and colleagues developed a bilayer wound dressing that combines tranexamic acid for clot stabilization with nitric oxide and propolis for antibacterial activity. The formulation produced rapid fibrin-network formation and strong reductions in bacterial colony counts in laboratory assays, while its clinical and in vivo performance remains to be established.

• L-Phe Nanostructures Sensitize Tumors to ICB

  2026-08-27

  A Nature Nanotechnology study shows that metal-ion-chelating L-phenylalanine nanostructures can reprogram dendritic-cell electrophysiology and, when combined with short-term starvation, improve immune checkpoint blockade responses. The work links potassium efflux, calcium influx, NLRP3 inflammasome activation, and NF-κB signaling to tumor-specific cytotoxic T-cell immunity, while also highlighting important translational limitations.

• Berberine Hydrochloride and the Gut–Bone Axis

  2026-08-27

  Berberine research is moving beyond isolated AMPK and antimicrobial narratives toward integrated metabolic, intestinal, and osteoimmune models. This thought-leadership analysis examines how Berberine hydrochloride can support mechanistic validation, salt-form benchmarking, and translational study design in gut–bone and metabolic research.

• Polybrene for Viral Transduction: Practical Workflow

  2026-08-26

  Learn how Polybrene improves viral gene delivery, supports selected lipid-mediated DNA transfection workflows, and can be adapted for specialized biochemical assays. This guide combines executable optimization steps with a careful interpretation of new FBXO22 degrader research, while separating established product uses from exploratory applications.

• Dabigatran A4077: Reliable Thrombin Assay Design

  2026-08-26

  Learn how Dabigatran (SKU A4077) can help distinguish thrombin-driven assay effects from nonspecific changes in cell viability or cytotoxicity workflows. This scenario-based guide covers formulation, concentration selection, coagulation endpoints, data interpretation, and practical vendor selection.

8450 records 1/564 page Next 12345 下5页 Last page